Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Prostatic Neoplasms 3Neoplasms 3Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hemangioma 2Carcinoma, Non-Small-Cell Lung 2Radiation Pneumonitis 1Radiation Injuries 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Lung Diseases, Interstitial 1Leukemia, Hairy Cell 1Leukemia 1Hepatitis 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Chemical and Drug Induced Liver Injury 1Bulbo-Spinal Atrophy, X-Linked 1Brain Neoplasms 1

Interventions

Cyclophosphamide 46fludarabine phosphate 24Busulfan 22Peripheral Blood Stem Cell Transplantation 20Radiotherapy 19Filgrastim 19Mycophenolic Acid 18Antilymphocyte Serum 18Cyclosporine 17Whole-Body Irradiation 16Rituximab 16Etoposide 16Methotrexate 15Melphalan 15Methylprednisolone 14Tacrolimus 12Cytarabine 12Vincristine 10Prednisone 10Doxorubicin 10Cord Blood Stem Cell Transplantation 10Thiotepa 6Granulocyte Colony-Stimulating Factor 6Leucovorin 5sargramostim 4fludarabine 4Daunorubicin 4glofitamab 3Sirolimus 3Methylprednisolone Hemisuccinate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Dendritic Cell Sarcoma, Interdigitating × Adrenal Cortex Hormones × Clear all
NCT03003520 2023-05-22

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Celgene

Phase 2 Completed
46 enrolled 20 charts
LymphoidSarcoma

Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡